Lam Research Soars 165% in a Year: Is LRCX Stock Still a Buy?

Lam Research (LRCX) has outperformed peers with a 164.8% one-year gain as demand for AI-related chips and advanced packaging accelerates; Q1 fiscal 2026 revenue rose 28% YoY to $5.32 billion, beating consensus by 2%, and non-GAAP EPS of $1.26 beat by 4.1% and rose 46.5% YoY. Non-GAAP operating margin expanded to 35% (+410 bps YoY) aided by Asian manufacturing expansion and strong systems/support demand; shipments for GAA and advanced packaging exceeded $1 billion in 2024 with management targeting >$3 billion in 2025. Zacks consensus implies FY26/FY27 revenue growth of 14.1%/12.5% and EPS growth of 15.9%/15.2%, and LRCX trades at a forward P/E of ~40.2 versus industry ~34.5, supporting a Zacks Rank #2 (Buy).

Analysis

Market structure: LRCX’s 164.8% YTD surge and 28% YoY revenue growth signal a strong reallocation of capex into etch/deposition and advanced packaging; primary beneficiaries are LRCX, ASML (node-leading tools) and foundries (TSM, Samsung) while commodity memory OEMs could lag if HBM-focused capacity shifts pricing/volume. Expect pricing power on select advanced-node tools and longer lead times (book-to-bill >1 implied), tightening supply for high-end equipment and preserving margins near current non-GAAP operating margin ~35% in the near term.

Risk assessment: Tail risks include abrupt China export controls or a 20–40% capex pullback from hyperscalers that could unwind orders and drop bookings by a quarter within 3–6 months, and operational execution risk from scaling Asian fabs. Near-term (days-weeks) volatility driven by quarterly book-to-bill and backlog prints; short-term (3–12 months) dependent on bookings cadence and customers hitting AI chip production timelines, long-term (2–4 years) driven by structural AI/HBM adoption and potential overcapacity in tools.

Trade implications: Base-case trade is selective long exposure to LRCX sized modestly (2–3% of portfolio) funded by trimming generalist tech; use 9–12 month call spreads to capture upside with defined risk (buy 20% OTM, sell 40% OTM). Relative-value: long LRCX vs short AMAT (or underweight AMAT) as LRCX has higher exposure to GAA/packaging growth; rebalance on bookings/revenue misses >5% vs consensus.

Contrarian angles: Consensus underweights cyclicality—if shipments to GAA/advanced packaging miss the management target of >$3B in 2025, expect a 25–35% downside re-rating as backlog re-optimizes. Historical parallels (2018–19 semicap bust) show rapid multiple compression despite strong tech end-markets; unintended consequence: aggressive supplier footprint expansion in Asia could lower long-term pricing power and margins if demand normalizes.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in LRCX (ticker LRCX) within 1–4 weeks, target a 12-month upside of +25–40%; place a hard stop-loss at -12% and trim to half position if quarterly bookings fall >10% vs consensus.
• Implement a 9–12 month LRCX call spread to leverage upside while limiting risk: buy 1.0 unit 20% OTM call and sell 1.0 unit 40% OTM call (size equivalent to 1–2% notional exposure), roll or close on earnings or implied vol moves >30%.
• Initiate a pair trade: long LRCX (2% weight) and short AMAT (1.5% weight) funded dollar-neutral; expect outperformance if GAA/advanced packaging penetration accelerates—close if relative performance reverses by >10% in 60 days.
• Overweight semiconductor equipment sector by +3% (funded by reducing mega-cap FAANG exposure by 3%) through H1 2026 to capture AI capex, but reduce exposure if sector-wide order momentum softens and book-to-bill drops below 1.0 for two consecutive quarters.
• Monitor three high-impact catalysts over the next 30–90 days: (1) LRCX quarterly bookings/backlog and guidance vs. consensus, (2) customer shipments for GAA/HBM reaching >$3B 2025 target, and (3) regulatory/export developments between US/China—trigger to reduce positions if any catalyst trends negative by >5% vs expectations.